# Characterization of a New Immunosuppressive and Antimicrobial Peptide, DRS-DA2, Isolated from the Mexican Frog, Pachymedusa dacnicolor

Claire Lacombe, Estefania Aleman-Navaro, Thierry Drujon, Veronica Martinez-Osorio, Emmanuelle Sachon, Erika Melchy-Pérez, Ludovic Carlier, Lorena Elizabeth Fajardo Brigido, Yannick Fleury, Christophe Piesse, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Claire Lacombe, Estefania Aleman-Navaro, Thierry Drujon, Veronica Martinez-Osorio, Emmanuelle Sachon, et al.. Characterization of a New Immunosuppressive and Antimicrobial Peptide, DRS-DA2, Isolated from the Mexican Frog, Pachymedusa dacnicolor. International Journal of Inflammation, 2024, 2024, pp.2205864. 10.1155/2024/2205864. hal-05397797

HAL Id: hal-05397797

https://hal.univ-brest.fr/hal-05397797v1

Submitted on 4 Dec 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
Research Article

Characterization of a New Immunosuppressive and Antimicrobial
Peptide, DRS-DA2, Isolated from the Mexican Frog,
*Pachymedusa dacnicolor*

Claire Lacombe ID,<fnref n="1" />,<fnref n="2" /> Estefania Aleman-Navaro,<fnref n="3" />,<fnref n="4" /> Thierry Drujon ID,<fnref n="1" />

Veronica Martinez-Osorio,<fnref n="3" />,<fnref n="4" /> Emmanuelle Sachon ID,<fnref n="1" />,<fnref n="5" /> Erika Melchy-Pérez ID,<fnref n="3" />

Ludovic Carlier ID,<fnref n="1" /> Lorena Elizabeth Fajardo Brigido,<fnref n="3" />,<fnref n="4" /> Yannick Fleury ID,<fnref n="6" />

Christophe Piesse,<fnref n="7" /> Guadalupe Gutiérrez-Escobedo,<fnref n="8" /> Alejandro De las Peñas,<fnref n="8" />

Irene Castaño,<fnref n="8" /> Florie Desriac ID,<fnref n="6" /> Jose Luis Beristain-Hernandez ID,<fnref n="9" />

Christophe Combadiere ID,<fnref n="10" /> Yvonne Rosenberg ID,<fnref n="3" /> and Constance Auvynet ID,<fnref n="3" />

Correspondence should be addressed to Constance Auvynet; constance.auvynet@ibt.unam.mx

Received 24 May 2023; Revised 21 October 2023; Accepted 17 November 2023; Published 13 January 2024

Academic Editor: Andrew Day

Copyright © 2024 Claire Lacombe et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.

Inflammatory and antimicrobial diseases constitute a major burden for society, and fighting them is a WHO strategic priority. Most of the treatments available to fight inflammatory diseases are anti-inflammatory drugs, such as corticosteroids or immunomodulators that lack cellular specificity and lead to numerous side effects. In addition to suppressing undesired inflammation and reducing disease progression, these drugs lessen the immune system protective functions. Furthermore, treating infectious diseases is more and more challenging due to the rise of microbial resistance to antimicrobial drugs. Thus, controlling the inflammatory process locally without compromising the ability to combat infections is an essential feature in the treatment of inflammatory diseases. We isolated three forms (DRS-DA2N, DRS-DA2NE, and DRS-DA2NEQ) of the same peptide, DRS-DA2, which belongs to the dermaseptin family, from the Mexican tree frog *Pachymedusa dacnicolor*. Interestingly, DRS-DA2N and DRS-DA2NEQ exhibit a dual activity by inducing the death of leukocytes as well as that of Gram-negative and Gram-positive bacteria, including multiresistant strains, without affecting other cells such as epithelial cells or erythrocytes. We showed that the death of both immune cells and bacteria is induced rapidly by DRS-DA2 and that the membrane is permeabilized, leading to the loss of membrane integrity. We also validated the capacity of DRS-DA2 to regulate the pool of inflammatory cells *in vivo* in a mouse model of noninfectious peritonitis. After the induction of peritonitis, a local injection of DRS-DA2N could decrease the number of inflammatory cells locally in the peritoneal cavity without inducing a systemic

<footnote n="1">¹Laboratoire des Biomolécules, LBM, Sorbonne Université, École Normale Supérieure, PSL University, CNRS, Paris, France</footnote>

<footnote n="2">²Faculté des Sciences, Université Paris Est-Créteil Val de Marne, Créteil, France</footnote>

<footnote n="3">³Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico</footnote>

<footnote n="4">⁴Posgrado de Ciencias Bioquímicas, Universidad Nacional Autónoma de México, Mexico City, Mexico</footnote>

<footnote n="5">⁵Plateforme MS3U Mass Spectrometry Sciences Sorbonne University, Fédération de Chimie Moléculaire de Paris Centre, FR2769, Sorbonne Université, Paris, France</footnote>

<footnote n="6">⁶LUBEM EA 3882, IUT Quimper, Université de Bretagne Occidentale, Quimper, France</footnote>

<footnote n="7">⁷Plateforme de Synthèse Peptidique, Institut de Biologie Paris-Seine (ISBS), Sorbonne Université, CNRS, Paris, France</footnote>

<footnote n="8">⁸IPICYT, División de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosí, Mexico</footnote>

<footnote n="9">⁹Hepatobiliary and Pancreatic Surgery Clinic, General Surgery Department La Raza National Medical Center, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico</footnote>

<footnote n="10">¹⁰Sorbonne Université, Institut National de Santé et de Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France</footnote>
effect, as no changes in the number of inflammatory cells could be detected in blood or in the bone marrow. Collectively, these data
suggest that this peptide could be a promising tool in the treatment of inflammatory diseases, such as inflammatory skin diseases, as it
could reduce the number of inflammatory cells locally without suppressing the ability to combat infections.

**1. Introduction**

Considering that chronic inflammation plays a central
role in the development of the majority of chronic-
degenerative diseases, but also of some infectious dis-
eases, including acute respiratory distress syndrome,
a common complication of various viral pneumonia
caused, for example, by coronaviruses, such as MERS-
CoV, SARS-CoV, and recent SARS-CoV-2 [1], it is of
great interest to identify new drug candidates to specif-
ically control the inflammatory process without com-
promising the ability of the body to combat infections.
Indeed, most of the anti-inflammatory drugs available
treat inflammatory diseases systemically and thus com-
promise the ability of the immune system to combat
infections [2, 3]. Antimicrobial peptides (AMPs), pro-
duced by skin and mucosal cells, among others, are fully
part of the innate immune system [4, 5]. Originally
identified for their microbicidal properties by killing
a large scale of Gram-negative and Gram-positive bac-
teria, fungi, and protozoa mainly by permeabilizing their
membrane, AMPs are now recognized to modulate the
immune system [6]. Among all the organisms producing
peptides, AMPs isolated from frogs present a broad range
of interesting biological activities in mammals. Notably,
a number of these AMPs have been identified to modulate
inflammatory processes by promoting the migration of
immune cells through the activation of chemotactic re-
ceptors and/or by stimulating the production of proin-
flammatory or anti-inflammatory cytokines [6], while
exhibiting antimicrobial properties against a wide range
of bacteria.

The aim of this study was to isolate and characterize,
in vitro and in vivo, a peptide that could be an alternative
candidate in the treatment of inflammatory diseases by
regulating the pool of inflammatory cells locally, rapidly, and
for a determined period of time. Thus, we tested the potential
of skin exudate extracted from the Mexican tree frog
Pachymedusa dacnicolor to present an immunosuppressor
effect. We found a fraction that regulated the pool of in-
flammatory cells by specifically inducing the death of immune
cells. Within that fraction, we isolated three forms of the same
peptide, differing only by the deletion of one or two residues
from the C-terminus. The longer peptide (DRS-DA2NEQ)
corresponds to the putative sequence determined from
cDNA, published in 1998 by Wechselberger [7], but the
corresponding peptide was not isolated. As these sequences
were rather close to a family of antimicrobial peptides, der-
maseptins, we also proceeded to test their antimicrobial ac-
tivity. We synthesized the two extreme forms of this peptide

(DRS-DA2NEQ and DRS-DA2N) and were able to dem-
onstrate that, in vitro, these peptides killed, at micromolar
concentrations, Gram-negative and Gram-positive bacteria,
including multiresistant strains, different Candida strains,
and human and mouse leukocytes, without affecting other
cells such as primary and transformed epithelial cells or
erythrocytes. In all cases, the shorter peptide (DRS-DA2N)
seemed to be more potent in inducing the death of immune
cells and bacteria than the longer one (DRS-DA2NEQ). We
showed that DRS-DA2 induced the death of both immune
cells and bacteria by rapidly inducing the permeabilization of
the membrane. Finally, we validated the capacity of this
peptide to induce specifically the death of inflammatory cells
in vivo in a murine model of inflammatory disease, non-
infectious peritonitis, and showed that the short form
DRS-DA2N exhibited a local, and not systemic, immuno-
regulatory effect by lessening the number of leukocytes in the
peritoneal cavity after induction of peritonitis.

**2. Materials and Methods**

2.1. *Animals.* All experiments involving living beings were carried out according to the guidelines of the Bioethics Committee of the Instituto de Biotecnología, UNAM (bioethics approval project 334/336 Pequeños péptidos de defensa: nuevas moléculas con capacidades inmunomoduladoras y antimicrobianas), and by authorized investigators. Specimens of *Pachymedusa dacnicolor* were captured in the state of Morelos (Mexico) and housed as previously described [8]. 10-week-old male or female C57BL/6 or Balb/c mice were kept in pathogen-free conditions with food and water available *ad libitum* and housed in a 12 h light/12 h dark (100–500 lux) cycle.

2.2. Peptide Purification and Identification by Mass Spectrometry. 200 µL of fresh skin exudate was recovered by gently squeezing the lateral-dorsal portion of the frog's skin, as described [8]. For identification by mass spectrometry, samples were prepared according to the "dried-droplet" method [9] with CHCA (α-cyano-4-hydroxycinnamic acid, Applied Biosystems) (5 mg/mL) as the matrix in ACN/ aqueous 0.1% TFA (1:1). MALDI-TOF experiments were performed using a 4700 proteomic analyzer apparatus (Applied Biosystems, Courtaboeuf, France) fitted with a pumped diode laser Nd:YAG: λ = 355 nm, a pulse duration of 4 ns, and a repetition rate of 200 Hz. MALDI-TOF/TOF experiments were performed under CAD (N₂, 5.3 × 10⁻⁵ Pa) at 1 keV (collision energy). Precursor ion window is +/- 2u. MS and MS/MS experiments were externally calibrated using classical peptides mixtures.
**2.3. Solid-Phase Peptide Synthesis.** Peptides were synthesized by automated solid-phase peptide synthesis using Fmoc/tBu chemistry on Activo-P11 (Activotec) and were then purified by HPLC (Waters, C18 column). Identities of the peptides were validated by MALDI-TOF mass spectrometry (MS Voyager Applied Biosystems). Considering the presence of one tryptophan residue in the sequence, concentrations were determined by UV spectroscopy (Nanodrop, Labtech.com) assuming an extinction coefficient for tryptophan ε<sub>280</sub> = 5 600 M<sup>-1</sup>·cm<sup>-1</sup>.

**2.4. Circular Dichroism (CD) Spectroscopy.** The CD spectra of the peptides were recorded as previously described [10]. Measurements were carried out in 10 mM Tris buffer at pH 7.4 and in the presence of POPC, POPG, and POPG-POPC (25:75) LUVs or POPG-POPE (25:75) LUVS to mimic *E. coli* inner membrane composition at a peptide/lipid molar ratio of 1/50. Dichroic spectra were corrected by subtracting the background obtained for each peptide-free solution. An analysis of CD spectra was conducted after smoothing, and conversion to molar ellipticity was calculated as follows: θ = θobs/(10xnxl), where θobs is the observed ellipticity, n is the number of bonds, c is the peptide concentration in mol. L<sup>-1</sup>, and l is the path length in cm.

**2.5. NMR Spectroscopy and Structure Calculations.** The structure of DRS-DA2N bound to SDS micelles was determined by solution-state NMR spectroscopy as previously described [11]. In brief, 2D ¹H-¹H TOCSY, 2D ¹H-¹H NOESY (80 ms mixing time), and 2D ¹H-¹³C HSQC experiments were recorded at 40°C on a Bruker 500 MHz Avance III spectrometer equipped with a 5 mm TCI cryoprobe. NMR samples contained 800 µM DRS-DA2N and 80 mM SDS-d25 (Eurisotop) in either 600 µL H₂O/D₂O (95:5) or 100% D₂O. 324 interproton distance restraints (121 intraresidual, 102 sequential, and 95 medium-range) were derived from NOESY cross-peak intensities, and 50 dihedral angle restraints (25 Φ and 25 Ψ) were predicted by TALOS-N from ¹³Cα, ¹³Cβ, ¹Hα, and ¹HN chemical shifts (Table S1) [11]. Structures were calculated by torsion angle dynamics in CNS and refined in an explicit layer of water including an electrostatic energy term in the energy function [12].

**2.6. Cell Preparation.** Human leukocytes were provided by the « Banco de Sangre del Hospital Regional del IMSS » and the Centro Estatal de la Transfusión Sanguínea in Cuernavaca, Morelos, Mexico. Institutional committees approved the acquisition and isolation of human peripheral blood leukocytes. Human leukocytes and erythrocytes were obtained as previously described [8]. Mouse bone marrow cells (MBMCs) and erythrocytes were obtained from C57BL/6 or Balb/c mice [13]. Mouse epithelial cells were isolated from C57BL/6 mice, and human epithelial cells were recovered from surgery residues. In brief, intestinal tissues were minced and

digested in 450-U/mL collagenase I, 125-U/mL collagenase XI, 60-U/mL hyaluronidase, and 60-U/mL DNase for 1 hour before gradient density centrifugation on Histopaque-1083 (Sigma-Aldrich, St. Louis, MO). A549 cells (ATCC CCL-185), a human lung carcinoma cell line, were cultivated at 37°C in a humid atmosphere and 5% CO₂, with DMEM advanced medium (Gibco®) supplemented with 5% of fetal bovine serum (FBS), 2 mM of glutamine, 100 U of penicillin, and 50 µg/mL of streptomycin (Gibco®). Jurkat E6-1 cells were cultured in an RPMI medium supplemented with 5% fetal bovine serum.

**2.7. Cytotoxic Assay.** 5.10⁵ mouse or human leukocytes or primary epithelial cells, A549 or Jurkat E6-1 cells, were incubated in 100 µl RPMI or DMEM containing 0.5% BSA and 10 nM HEPES with the peptides at different concentrations for 2 hours at 37°C, 5% CO₂. Incubation of the cells with DMSO 30% was used as a positive control. For the kinetic assay, the cells were incubated with the peptides for different time periods. Viability of leukocytes and Jurkat cells was determined by adding a viability dye (eFluor 780) and counted by FacsCanto flow cytometry with a predetermined number of beads (Polybead, Carboxylate Microspheres, Polysciences, Inc., Le Perray-en-Yvelines, France) added to the samples. Mouse leukocytes were stained with anti-mouse Ly6G-PE, anti-mouse NK1.1-PE, anti-mouse CD11b-PerCP, and anti-mouse F4/80-APC (BD Biosciences, Rungis, France). Human leukocytes were stained with anti-human CD45-PB, anti-human CD16-PE-Cy7, anti-human CD56-PE-Cy7, anti-human CD14-FITC, anti-human CD3V500, anti-human CD8-APC, and anti-human CD4-PE. Data were analyzed with FlowJo.

For the cell line A549, viability was assessed by the CCK8 assay (DoJindo) as indicated by the manufacturer. In brief, 100 µL of cell suspension was dispensed (12 500 cells/well) in a 96-well plate. After 24-hour preincubation in a humidified incubator (37°C, 5% CO₂), 10 µL of various concentrations of peptides was added, and the plaque was incubated for 1 h in the incubator. 10 µL of CCK-8 solution was then added to each well of the plate. The absorbance at 450 nm was measured after 3 h incubation.

**2.8. Hemolytic Tests.** Blood from a mouse or healthy adult donor was centrifuged at 800 × g for 10 minutes at 4°C. The pellet containing red blood cells was then washed three times in 10 volumes of PBS and was diluted in 4% (v/v) in PBS. Blood and peptides at different concentrations were then incubated at 37°C for one hour. Cells were centrifuged 1500 × g for 5 minutes at room temperature. Hemolysis was measured in the supernatant at 550 nm. Red blood cells lysed with 1% Triton X-100 was used as a control, achieving 100% hemolysis. Percent hemolysis was calculated using the following formula: % hemolysis = 100% × [(A - A0)/(At - A0)], where A represents the absorbance of the peptide sample at 550 nm and A0 and At represent 0% and 100% hemolysis determined in 10 mM PBS and 0.1% Triton X-100, respectively.
2.9. *Antimicrobial Assays.* The minimum inhibitory concentration (MIC) was determined by a liquid test in 96-well microplates as previously described [13]. 100 µL of the sample to be tested was distributed in triplicate to obtain a range of final concentrations from 100 to 0.2 µM in the wells. 90 µL of bacterial suspension (5 × 10⁵ CFU/mL for Gram-negative bacteria and 5 × 10⁵ CFU/mL for Gram-positive strains in Mueller-Hinton broth) were added to each well [14]. The microtiter plates were incubated at 37°C overnight. The optical density of the wells was measured at 620 nm, and the results were interpreted by calculating the percentage of growth in each well according to the formula: % growth = (OD₆₀₀ well - OD₆₀₀ T0) / (OD₆₀₀ of T100 - OD₆₀₀ T0) * 100, where OD₆₀₀ T100 = OD₆₀₀ growth control (bacterial suspension without the test sample, 100% growth), OD₆₀₀ T0 = OD₆₀₀ of sterility control (culture medium + bacteria + 10 µL formaldehyde, 0% growth) well, and OD₆₀₀ = OD₆₀₀ of the well which was desired to calculate the percentage of growth (+ bacterial suspension test sample). MIC is the minimum concentration of the peptide that inhibits bacterial growth after incubation at 37°C for 20 hours.

The minimum bactericidal concentration (MBC) is defined as the minimum concentration of the peptide killing 99.9% of bacteria after incubation at 37°C for 20 hours. This test consisted of the spreading of the contents of the wells where the peptide inhibited bacterial growth on a Petri dish (MH agar), followed by incubation for 24 h at 37°C.

2.10. *Antifungal Assay: Strains and Growth Conditions.* The fungal pathogens *C. glabrata* standard strain CBS138 [15] and *C. albicans* strain SC5314 [16] were grown in rich (YPD) media. Yeast extract-peptone-dextrose (YPD) medium was prepared, contained yeast extract at 10 g/L and peptone at 20 g/L, and was supplemented with 2% glucose. *C. albicans* and *C. glabrata* cells were grown for 48 h at 30°C and diluted into fresh YPD media containing different concentrations of each peptide (DRS-DA2N and DRS-DA2NEQ): 1.5, 3, or 15 µM. These cultures were grown in a Bioscreen C apparatus with constant shaking for 1,500 min, and OD₆₀₀ was determined every 15 min as described previously [17].

2.11. *Time Kill.* Time-killing experiments were achieved according to [18, 19] with minor modifications. The peptide's concentration was 1 × MIC and 2 × MIC. At the time points of 15, 30, 45, and 60 min and after homogenization, suspensions were diluted in 10 mM sodium phosphate buffer (pH 6.8) and spread onto MH agar plates. After overnight incubation at room temperature, CFUs were counted.

2.12. *In Vitro Peptide Stability.* One mL of RPMI supplemented with 25% (v/v) rat serum was equilibrated at 37°C for 15 min before adding the peptide (final concentration of 300 µM). At different time points, 300 µL of the reaction solution was removed and completed to 600 µL with 96% ethanol. The sample was cooled at 4°C for 15 min and then spun to precipitate serum proteins. The supernatant was

recovered and submitted to the viability assay as described in the cytotoxic assay section or analyzed by RP-HPLC on C18-300 100 × 4, 6 mm. A linear gradient from 100% buffer A (0.1% TFA in H₂O) to 60% of buffer B (0.1% TFA in ACN) was used over 10 min with a flow rate of 1 mL/min. The absorbance was detected at both 220 nm and 280 nm.

2.13. *Thioglycolate-Induced Peritoneal Inflammation.* C57BL/6 mice were injected intraperitoneally with 1 mL 3% (wt/vol) thioglycolate (Sigma-Aldrich, l'Ile d'Abeau, France) dissolved in sterile NaCl and then 14, 19, and 24 hours later injected i.p. with DRS-DA2N or DRS-DA2NEQ (15 µg/injection). NaCl was used as a negative control. Twelve hours after the last injection, mice were killed, and 3 mL of cold PBS was injected i.p. to harvest peritoneal cells, which were then stained with anti-mouse Ly6G-PE, anti-mouse NK1.1-PE, anti-mouse CD11b-PerCP, and anti-mouse F4/80-APC (BD Biosciences, Rungis, France). Blood and bone marrow were also collected and stained with the same antibodies. Cells and beads were then counted by FACSCalibur flow cytometry, and data were analyzed with FlowJo. Cells being CD11b<sup>hi</sup>Ly6G<sup>-</sup>NK1.1<sup>-</sup> are considered to be monocytes (Mo), CD11b<sup>hi</sup>Ly6G<sup>-</sup>NK1.1<sup>-</sup> F4/80<sup>+</sup> macrophages (MΦ), and CD11b<sup>hi</sup>Ly6G<sup>+</sup>NK1.1<sup>-</sup> neutrophils (PMN).

2.14. *Apoptosis/Necrosis Assays.* Induction of apoptosis or necrosis by the peptides was tested by incubating 5.10⁵ Jurkat E6-1 cells in 200 µL RPMI containing 10% FBS and 10 nM HEPES with the peptides at 5 µM for 2 hours at 37°C, 5% CO₂. A positive control was obtained by exposing the cells to UV light for 10 min (1 mJ/cm², Stratagene UV Stratalinker 2400), before incubating them for 4 hours at 37°C, 5% CO₂, RPMI 10% FBS. Cells were then washed, centrifuged, resuspended, and incubated 30 min at 4°C in the dark with Viability dye 780 (BioLegend). After washing the cells, Annexin-V-FITC in annexin-binding buffer was added, and the cells were incubated for 15 minutes at room temperature in the dark. The cells were fixed with PFA at a final dilution of 2% before being analyzed by FACSCanto flow cytometry.

2.15. *Peptide-Induced Permeabilization of the Inner Bacterial Membrane* [20]. Permeabilization of the *E. coli* ML35p membrane by both peptides was assayed by measuring the β-galactosidase activity with the chromogenic substrate o-nitrophenyl-β-D-galactopyranoside (ONPG). Bacteria were grown in 10% Mueller-Hinton broth with 50 µg/mL ampicillin, washed twice with the test buffer (10 mM phosphate, 100 mM NaCl at pH 7.4 and 300 µg/mL Mueller-Hinton broth), and diluted in the test buffer to an absorbance of 0.6 at 630 nm (mid-log phase). 50 µL aliquots of bacterial suspension were mixed with 25 µL pf the peptide at various concentrations and 25 µL ONPG (2 mM, i.e., 0.5 mM final) in a 96-well plate. The hydrolysis of ONPG was monitored by measuring the absorbance of released o-nitrophenol at 412 nm with a Fluostar Galaxy microplate reader (BMG LabTech, France) [8]. Data shown are the means of 3 independent experiments realized in duplicate.
2.16. *Membrane Depolarization.* *E. coli* cells were grown at 37°C to the mid-logarithmic phase and were collected by centrifugation (4000 x g, 10 min), before being resuspended in MH with 0.1 mg/mL BSA and were diluted in the same buffer to an OD~620~ of 0.6. The bacterial suspension was divided into 125 µL aliquots in 96-well microplates. 10 µL of DiSC~3~(5) in 1% DMSO was added in each well to a 10 µM final concentration. After 10 minutes, 10 µL of EDTA (15 mM final concentration) was added. After recording the baseline fluorescence, 5 µL of the aqueous peptide stock was added to the desired final concentration. The increase in the fluorescence intensity registers dye release upon reduction of the transmembrane potential. The fluorescence reading was monitored by using a microplate reader (BMG Fluostar) at an excitation wavelength of 620 nm and an emission wavelength of 670 nm.

2.17. *Preparation of Vesicles.* The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) were obtained from Avanti Polar Lipids, Inc., and used without further purification. Desired mixtures of phospholipids were first dried in glass tubes under nitrogen and then maintained under reduced pressure for at least 60 min. Lipid films were subsequently hydrated in PBS to yield a lipid concentration. The resulting dispersions were subjected to 5 freeze-thaw cycles by alternately placing the sample vial in a liquid nitrogen bath and a warm water bath (40°C). The large multilamellar vesicles (MLVs) were then extruded 11 times through polycarbonate membranes (100 nm pore size; Whatman, Maidstone, UK) on an Avanti mini-extruder apparatus (Avanti Polar Lipids, Inc., Albaster, AL) equipped with polycarbonate membranes (at 100 and 400 nm cutoff) to generate large unilamellar vesicles (LUVs).

2.18. *ANTS/DPX Leakage Assay.* The vesicles of POPE/POPG (75/25) at 25 mM concentration were obtained as previously described and suspended in a solution of 12.5 mM ANTS and 45 mM DPX in 10 mM HEPES. After freeze-thaw and extrusion, LUVs were separated from external ANTS/DPX by ultracentrifugation (3 × 50 000 rpm, 15 min). Final lipid concentration was measured by the method of Rouser.

To measure the leakage of DPX, the vesicles were diluted to a concentration of 0.5 mM lipid. The peptide was added to individual samples at concentrations from 0.5 µM (*P*: L = 1:1000) to 50 µM (*P*: L = 1:10). ANTS fluorescence was monitored using a fluorimeter (excitation = 350 nm; emission = 530 nm) or a fluorescence plate reader (excitation filter wavelength/bandpass = 340/11; emission 530/25.

When leakage has stopped or slowed significantly (generally 10–60 minutes), the final ANTS fluorescence was measured. Fractional leakage was calculated as $(F_{\text{sample}} - F_{\text{initial}})/(F_{\text{lysed}} - F_{\text{initial}})$.

2.19. *Intrinsic Tryptophan Fluorescence.* The fluorescence spectra of DRS-DA2 peptides were recorded from 295 to 475 nm with excitation at 280 nm in a spectrofluorometer using a quartz cuvette (Jobin Yvon Horiba spectrometer H 10-61 UV, Kyoto, JAP; Biologic Science Instruments ALX 250, MM 450, PMS 250; Software: Bio-Kine 32 V4.60, Grenoble, F). 150 µL of a 20 µM peptide solution was placed in a 10 × 2 mm cuvette (Hellman Analytics, Müllheim, GER), and increasing amounts of the lipid solution were added to obtain lipid concentrations of 10, 25, 50, 100, 200, 500, 1500, and 3000 µM. After each addition, the tryptophan residue of the peptide was excited at 280 nm, and the emission spectra were recorded from 300 to 480 nm. The intensity of the emission was first plotted against the wavelength of the emitted fluorescence of tryptophan. Taking into consideration that the peptide's concentration changes during the experiment because of the addition of amounts of lipid-containing buffer, the data were formatted so that all information corresponds to the same peptide concentration. The subsequent normalization of the graphs allows for an easy comparison of the results from different experiments. We chose to calculate $\Delta\lambda_{\text{max}}$—hence the difference between $\lambda_{\text{max}}$ at any concentration of lipid and the $\lambda_{\text{max}}$ of the peptide solution without added liposomes—and to plot the values against the ratio (concentration of lipid)/(concentration of peptide). An apparent binding constant equivalent to the concentration of lipid at which the lipid-induced blue shift was half-maximal ($K_L$) was thus determined.

### 3. Results

Isolation of a new peptide belonging to the dermaseptin family with immunosuppressive properties.

As previously reported [11], *Pachymedusa dacnicolor* skin exudate was extracted and purified to homogeneity by a two-step protocol. In brief, 1.1 mL of skin exudate recovered by gently squeezing the skin parotid glands was first fractionated on a Sephadex G-50 column (Fig S1), and the three fractions obtained were incubated with human leukocytes at 37°C, 5% CO~2~. After 30 min of incubation with fraction I at a concentration of 100 µg mL~1~, 100% of the cells were dead (insert Fig S1). High molecular weight fraction I was then purified by RP-HPLC (Figure 1(a)). Among all fractions incubated with leukocytes, the fraction with a retention time of 49 min was found to induce the death of leukocytes (data not shown). This RP-HPLC fraction was further analyzed by mass spectrometry for peptide identification and *de novo* sequencing. The MALDI-TOF/TOF analysis of the RP-HPLC fraction revealed three peptides corresponding to monoprotonated ions [M+H]~+~ with at m/z 3337.82, 3209.77, and 3080.74 for the first isotope (monoisotopic masses), respectively, and consistent with dermaseptin-like peptides (Figure 1(b)). The three peptides, identified with mass precision in the 10–20 ppm range, only differ from each other by the loss of one residue (Q) or two residues (EQ) at their C-terminus. The nontruncated sequence, which corresponds to the sequence of DRS-
<figure><img src="image_3.png" /></figure>

<table><thead><tr><th>Sequence determination</th><th>Sequence</th><th>Name</th><th>m/z [M+H]<sup>+</sup> observed</th><th>m/z [M+H]<sup>+</sup> theoretical</th><th>Error (ppm)</th></tr></thead><tbody><tr><td>Predicted from <i>P. dacnicolor</i> DNA</td><td>ALWKTLLKKVGKVAGKAVLNAVTNMANQNEQ</td><td>PD-2-2</td><td>-</td><td>-</td><td>-</td></tr><tr><td>De novo sequencing</td><td>ALWKTLLKKVGKVAGKAVLNAVTNMANQNEQ</td><td>DRS-DA2NEQ</td><td>3337.82</td><td>3337.8777</td><td>17.28</td></tr><tr><td>De novo sequencing</td><td>ALWKTLLKKVGKVAGKAVLNAVTNMANQNE</td><td>DRS-DA2NE</td><td>3209.77</td><td>3209.8191</td><td>15.29</td></tr><tr><td>De novo sequencing</td><td>ALWKTLLKKVGKVAGKAVLNAVTNMANQN</td><td>DRS-DA2N</td><td>3080.74</td><td>3080.74765</td><td>11.8</td></tr></tbody></table>

(b)

FIGURE 1: Isolation and purification of a new immunosuppressor peptide, dermaseptin DRS-DA2. (a) Fraction I that was shown to induce the death of leukocytes was purified by RP-HPLC. Among all the fractions tested for an immunosuppressive effect, the one with a retention time of 49 min (arrow) induced the death of leukocytes. (b) *De novo* characterization by MALDI-TOF/TOF mass spectrometry identified three peptides in fraction 49: DRS-DA2NEQ, DRS-DA2NE, and DRS-DA2N. Those peptides were all carboxylated at their C-terminus. Isotopic masses are given for the protonated molecules, and mass errors are given in ppm. The sequence of the nontruncated peptide corresponds to PD-2-2.

DA2NEQ, had been predicted from frog DNA in 1998 [7] but never confirmed until now, as the corresponding peptide was not isolated. These peptides were named DRS-DA2N, DRS-DA2NE, and DRS-DA2NEQ (Figure 1(b)). Synthetic peptides were used for their characterization.

DRS-DA2 peptides were then structurally characterized by circular dichroism (CD) and NMR. Antimicrobial peptides are generally unstructured in aqueous solution and tend to adopt a well-defined conformation in contact with membranes. CD spectra were recorded in the presence of Tris buffer (10 mM) or negatively charged LUVs composed of POPE and POPG phospholipids, with a 3:1 ratio that reflects the PE/PG ratio in the inner membrane of *E. coli*. In the presence of negatively charged LUVs, both DRS-DA2N and DRS-DA2NEQ adopted dichroic spectrum characteristics of an α-helix conformation, like the one obtained for melittin, a well-known pore-forming peptide [21, 22], as indicated by the two intense negative bands detected around 208 and 222 nm. However, a difference in the percentage of helicity was observed between the peptides, indicating that DRS-DA2N (91%) seemed to be better structured than DRS-DA2NEQ (62%) and melittin (77%). As expected, Scr (KGNVLVKAAMLTKVLAKNKGVQNANALTW), the random form of DRS-DA2N, remained unstructured

(Figure 2(a)). On the contrary, in the presence of Tris buffer, all peptides remain unstructured (Fig. S2). The conformation of DRS-DA2N was further characterized at the residue level by solution-state NMR in the presence of SDS micelles that mimic the amphipathic properties of the lipid bilayer. Analysis of NMR data indicated that the region from L2 to A26 adopted a well-defined helical structure, while the terminal residues A1 and N27-N29 are rather unstructured (Fig. S3). The structure of DRS-DA2N exhibited a pronounced amphipathic character with the hydrophobic face predominantly formed by A, L, and V residues and the hydrophilic face containing 4 K residues (K8, K9, K12, and K16) (Figure 2(b)). The interfacial position of residue K4 allowed the ammonium group of its long-side chain to potentially interact with the phospholipid head groups at the surface of the bacterial membrane or to make π-cation interactions with the aromatic group of W3 on the hydrophobic face of the helix. Despite its weak helical propensity, the presence of two G residues (G11 and G15) in a GXXXG motif did not interrupt the helical conformation in the central region of the peptide (Figures S3a and 3(b)). Altogether, these results demonstrate that DRS-DA2 is structured in an α-helix and that DRS-DA2N seems better structured than DRS-DA2NEQ.
<figure><img src="image_4.png" /><figcaption>FIGURE 2: Structural properties of DRS-DA2N and DRS-DA2NEQ. (a) Far-UV CD spectra of DRS-DA2N, DRS-DA2NEQ, melittin, and Scr in POPE: POPG (75:25) LUVs. Data shown are representative of at least three different experiments. (b) NMR structure of DRS-DA2N bound to SDS micelles (ribbon representation of the lowest-energy conformer). Side chains of residues forming the polar and hydrophobic faces are represented by sticks.</figcaption></figure>

### 3.1. DRS-DA2 Induces Rapidly the Death of Immune Cells but Is Not Toxic for Erythrocytes or Epithelial Cells.
The viability of different populations of human and mouse leukocytes (neutrophils, monocytes, NK, and T cells) was measured after incubating the cells for two hours at 37°C, 5% CO₂ with various concentrations of DRS-DA2N and DRS-DA2NEQ, as well as Scr as control. Both peptides DRS-DA2N and DRS-DA2NEQ induced the death of human (Figure 3(a)) and mouse (Fig. S4) neutrophils (PMN), NK, and T cells with an $LC_{50}$ of around 5 µM (Table 1), with DRS-DA2N being slightly more potent than DRS-DA2NEQ. As predicted, Scr did not induce the death of any of the human or mouse leukocyte populations.

To assess the kinetics of peptide-induced cell death, leukocytes were incubated with DRS-DA2N and DRS-DA2NEQ at a concentration of 10 µM for different times, up until two hours. As observed in Figure 3(b), around 50% of the leukocytes were killed after 15 min of incubation with both DRS-DA2N or DRS-DA2NEQ. However, DRS-DA2N seems to induce the death of the cells in a slightly faster way.

To figure out if the induction of cell death by the peptides was restricted to leukocytes or affected other cell lineages, both peptides at different concentrations were incubated with human (Figure 4(a)) and mouse (Fig. S5) red blood cells, human (Figure 4(b)) and mouse (Fig. S5) primary epithelial cells, and the human tumoral epithelial cell line (A549) (Figure 4(c)). Interestingly, at the concentrations they induce the death of 100% of leukocytes (10 µM), none of the peptides induced the death of any of these cell types.

These results suggest that DRS-DA2N and DRS-DA2NEQ preferentially induce the death of leukocyte lineage cells but not that of other cells, such as epithelial cells or erythrocytes.

### 3.2. DRS-DA2 Has a Broad-Spectrum Microbicidal Capacity.
The antibacterial properties of DRS-DA2N, DRS-DA2NEQ, the control peptide Scr, and melittin as a reference pore-forming peptide were tested on a series of Gram-positive and Gram-negative strains. As presented in Table 2, both peptides exhibited a wide spectrum of action, which was however greater on Gram-negative than on Gram-positive bacteria even if some MICs ≤ 6.3 µM were observed for S. aureus ATCC 6538 and ST 1065, S. epidermidis BM 3302, and Enterococcus faecalis CIP 103015. Interestingly, DRS-DA2N was generally four times more potent than DRS-DA2NEQ and also than melittin. Particularly, for the E. coli β-lactamase-resistant strain, the MIC observed for DRS-DA2N was 1.6 µM, whereas the one for melittin was only 6.25 µM. As predicted, Scr did not exhibit any bacterial activity.

As DRS-DA2N appeared to be more potent than DRS-DA2NEQ, its antibacterial activity was evaluated on various skin multiresistant strains and compared to reference antibiotics (Table 3). Interestingly, DRS-DA2N was active on multiresistant Gram-positive and Gram-negative strains and exhibited MICs lower than the reference antibiotics, even for Gram-positive strains. In the case of the clinical isolates of
<figure><img src="image_5.png" /><figcaption>FIGURE 3: DRS-DA2N and DRS-DA2NEQ induce the death of human leukocytes. (a) Different populations of human leukocytes (PMN, Mo, NK, and T cells) were incubated for two hours at 37°C, 5% CO₂ in the presence of various concentrations of DRS-DA2N, DRS-DA2NEQ, or Scr. The percentage of live cells was determined by flow cytometry. (b) Total human leukocytes were incubated in the presence of DRS-DA2N, DRS-DA2NEQ, and Scr at a concentration of 10 µM for different time periods until 2 hours, and the percentage of live cells was determined by flow cytometry. Data represent three independent experiments run in triplicate.</figcaption></figure>

<table><caption>TABLE 1: $LC_{50}$ (µM) of DRS-DA2N and DRS-DA2NEQ.</caption><thead><tr><th rowspan="3"></th><th colspan="4">LC<sub>50</sub> (µM)</th></tr><tr><th colspan="2">DRS-DA2N</th><th colspan="2">DRS-DA2NEQ</th></tr><tr><th>Human cells</th><th>Mouse cells</th><th>Human cells</th><th>Mouse cells</th></tr></thead><tbody><tr><td>PMN</td><td>7.5</td><td>6</td><td>7</td><td>7.5</td></tr><tr><td>Mo</td><td>4</td><td>5</td><td>4</td><td>7</td></tr><tr><td>T cells</td><td>4</td><td>3</td><td>5</td><td>5</td></tr><tr><td>NK cells</td><td>4</td><td>3</td><td>5</td><td>4</td></tr></tbody></table>

P. acnes, responsible for acne vulgaris, DRS-DA2N was less effective than the reference antibiotic doxycycline, yet it exhibited good activity.

To further broaden the potential of DRS-DA2N and DRS-DA2NEQ to function as anti-microbial agents, we tested the antifungal activity of DRS-DA2N and DRS-DA2NEQ on C. glabrata CBS138 and C. albicans SC5314, two strains responsible for most bloodstream infections worldwide, associated with high mortality rates [23]. C. glabrata CBS138 and C. albicans SC5314 were grown in the presence of DRS-DA2N and DRS-DA2NEQ at various concentrations. Although the peptides did not inhibit the growth of C. glabrata CBS138 and C. albicans SC5314, the lag phase was extended for both fungal pathogens, as compared to the no-treatment culture. In the absence of either peptide, C. albicans started growing at 125 min, but in the presence of DRS-DA2N (3 or 15 µM), the lag phase was

extended to 250 min and that of C. glabrata up to 500 min (Figure 5(a)). In the presence of DRS-DA2NEQ, C. albicans also showed an extended lag phase and a reduced doubling time at 15 µM. At that same concentration of DRS-DA2NEQ, C. glabrata showed an extended lag phase with no effect in doubling time (Figure 5(b)). These data indicate that both peptides DRS-DA2N and DRS-DA2NEQ have also antifungal activities.

We next investigated if, like leukocytes, bacteria were killed rapidly by DRS-DA2N and DRS-DA2NEQ. Time-kill curves of DRS-DA2N and DRS-DA2NEQ against E. coli ATCC8739 were performed. Curves representing the amount of surviving bacteria (CFU/mL) in the absence or presence of DRS-DA2N, DRS-DA2NEQ, melittin, or omiganan, an antibiotic used in the treatment of skin infections at their MIC concentrations, are presented in Figure 6. Interestingly, the growth of E. coli ATCC8739 was stopped rapidly by DRS-DA2N, DRS-DA2NEQ, and melittin, as all the bacteria were killed after only 15 min of incubation with either peptide at 37°C. In contrast, omiganan needed a much longer time to be active.

Altogether, these data show that DRS-DA2 peptides have rapid antibacterial and antifungal activities.

### 3.3. DRS-DA2 Has a Short Half-Life in the Presence of Serum.
Before assessing the anti-inflammatory activity of the peptides *in vivo*, the stability of DRS-DA2 to proteases was investigated. DRS-DA2N at a final concentration of
<figure><img src="image_6.png" /><figcaption>FIGURE 4: DRS-DA2N and DRS-DA2NEQ are not toxic for erythrocytes or epithelial cells. (a) Human erythrocytes in PBS were incubated with various concentrations of DRS-DA2N and DRS-DA2NEQ for one hour. Triton 1% was used as a positive control. Hemoglobin release was monitored by measuring the absorbance at 550 nm (mean of 3 independent experiments run in triplicate). (b) Human primary epithelial cells were incubated with DRS-DA2N and DRS-DA2NEQ at the indicated concentrations for 2 hours at 37°C, 5% CO₂. The percentage of live cells was determined by flow cytometry. (c) A549 cells were incubated for 1 hour at 37°C, 5% CO₂ in the presence of increasing concentrations of the peptides. The percentage of live cells was determined by the CCK8 assay. Experiments were run in duplicate.</figcaption></figure>

<table><caption>TABLE 2: Antimicrobial activities of DRS-DA2N and DRS-DA2NEQ on Gram-negative and Gram-positive strains.</caption><thead><tr><th rowspan="3"></th><th colspan="8">Antimicrobial activity: MIC/MBC (pM)</th></tr><tr><th colspan="2">DRS-DA2N</th><th colspan="2">DRS-DA2NEQ</th><th colspan="2">SAT</th><th colspan="2">Melittin</th></tr><tr><th>MIC</th><th>MBC</th><th>MIC</th><th>MBC</th><th>MIC</th><th>MBC</th><th>MIC</th><th>MBC</th></tr></thead><tbody><tr><td colspan="9"><strong>Gram-negative strains</strong></td></tr><tr><td>E. coli ATCC 8739</td><td>0.8</td><td>0.8</td><td>1.6</td><td>1.6</td><td>&gt;50</td><td>&gt;50</td><td>3.2</td><td>3.2</td></tr><tr><td>E. coli K12</td><td>3.2</td><td>6.3</td><td>12.5</td><td>12.5</td><td>n.d</td><td>n.d</td><td>12.5</td><td>12.5</td></tr><tr><td>E. coli ML35p</td><td>0.8</td><td>0.8</td><td>1.6</td><td>1.6</td><td>n.d</td><td>n.d</td><td>12.5</td><td>12.5</td></tr><tr><td>E. coli P7 (BLSE)*</td><td>1.6</td><td>12.5</td><td>12.5</td><td>50</td><td>n.d</td><td>n.d</td><td>6.3</td><td>6.3</td></tr><tr><td>P. aeruginosa ATCC 9027</td><td>3.2</td><td>3.2</td><td>6.3</td><td>6.3</td><td>&gt;50</td><td>&gt;50</td><td>6.3</td><td>6.3</td></tr><tr><td>P. aeruginosa ATCC 27853</td><td>12.5</td><td>50</td><td>50</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>50</td><td>&gt;50</td></tr><tr><td>K. pneumoniae CIP 52.211</td><td>0.8</td><td>0.8</td><td>0.8</td><td>0.8</td><td>n.d</td><td>n.d</td><td>12.5</td><td>12.5</td></tr><tr><td>K. oxytoca CIP 7932</td><td>3.2</td><td>6.3</td><td>12.5</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>zs</td><td>No</td></tr><tr><td>S. enterica CIP 8297</td><td>12.5</td><td>25</td><td>50</td><td>100</td><td>n.d</td><td>n.d</td><td>50</td><td>&gt;50</td></tr><tr><td>Y. ruckeri ATGG 29473</td><td>3.2</td><td>12.5</td><td>25</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>6.3</td><td>12.5</td></tr><tr><td colspan="9"><strong>Gram-positive strains</strong></td></tr><tr><td>S. aureus ATCC 6538</td><td>1.6</td><td>3.2</td><td>6.3</td><td>12.5</td><td>&gt;50</td><td>&gt;50</td><td>6.3</td><td>6.3</td></tr><tr><td>S. aureus MRSA*</td><td>25</td><td>&gt;50</td><td>100</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>6.3</td><td>12.5</td></tr><tr><td>S. aureus ST 1065</td><td>6.3</td><td>6.3</td><td>12.5</td><td>25</td><td>n.d</td><td>n.d</td><td>10</td><td>10</td></tr><tr><td>S. epidermidis BM 3302</td><td>6.3</td><td>25</td><td>12.5</td><td>&gt;50</td><td>n.d</td><td>n.d</td><td>10</td><td>10</td></tr><tr><td>L. monocytogenes SOR 100</td><td>25</td><td>25</td><td>100</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>1.5</td><td>3.2</td></tr><tr><td>E. faecalis CIP A186</td><td>50</td><td>&gt;50</td><td>100</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>12.5</td><td>12.5</td></tr><tr><td>L. garvieae ATCC 43921</td><td>25</td><td>50</td><td>100</td><td>&gt;100</td><td>n.d</td><td>n.d</td><td>6.3</td><td>25</td></tr><tr><td>E. faecalis CIP 103015</td><td>6.3</td><td>6.3</td><td>12.5</td><td>12.5</td><td>&gt;50</td><td>&gt;50</td><td>1.6</td><td>1.6</td></tr><tr><td>K. rhizophila ATCC 9341</td><td>0.8</td><td>1.6</td><td>1.6</td><td>1.5</td><td>n.d</td><td>n.d</td><td>0.8</td><td>0.8</td></tr></tbody></table>

<table><caption>TABLE 3: Antibacterial activities of DRS-DA2N on some skin multiresistant bacteria in comparison with reference antibiotics.</caption><thead><tr><th>Bacterial strains</th><th>DRS-DA2N (µM)</th><th>ATB (µM)</th></tr></thead><tbody><tr><td>S. aureus ATCC 700699 (MecA+)</td><td>&gt;5.2</td><td>&gt;43.8<sup>a</sup></td></tr><tr><td>S. epidermidis ST20140436 (MecA+)</td><td>5.2</td><td>&gt;43.8<sup>a</sup></td></tr><tr><td>E. coli OXA-48 (carbapenemase)</td><td>5.2</td><td>&gt;43.8</td></tr><tr><td>Acinetobacter johnsonii (carbapenemase)</td><td>1.3</td><td>&gt;29.3<sup>b</sup></td></tr><tr><td>Propionibacterium acnes (clinical isolate)</td><td>1.3</td><td>0.13<sup>c</sup></td></tr><tr><td>Propionibacterium acnes (clinical isolate)</td><td>0.6</td><td>0.27<sup>c</sup></td></tr></tbody></table>

ATB: reference antibiotics, a: amoxicillin, b: ceftazidime, and c: doxycycline.

<footnote>*Multiresistant strains.</footnote>
<figure><img src="image_7.png" /><figcaption>FIGURE 5: DRS-DA2N and DRS-DA2NEQ present antifungal activities. C. albicans and C. glabrata cells were grown for 48 h at 30°C and diluted into fresh YPD media containing DRS-DA2N (a) and DRS-DA2NEQ (b) at 1.5, 3, or 15 µM. OD₆₀₀ was determined every 15 min. The control corresponds to fungi without any peptide.</figcaption></figure>

<figure><img src="image_8.png" /><figcaption>FIGURE 6: DRS-DA2N and DRS-DA2NEQ induce the death of Gram-negative bacteria rapidly. The death of bacteria was measured by the time-killing assay (TKA). Curves representing the amount of surviving bacteria (CFU/mL) in the absence or presence of DRS-DA2N, DRS-DA2NEQ, melittin, or omiganan at their MIC concentrations. The control corresponds to bacteria without any peptide.</figcaption></figure>

300 µM was incubated in the presence of rat serum at 37°C for different times (0, 0.5, 1, 2, 3, 4, and 24 h) before being recovered and analyzed by RP-HPLC. Peptide degradation was followed at 220 and 280 nm. Quantification of the remaining peptide DRS-DA2N over time was performed by comparing the areas of the intact peptide DRS-DA2N with the sum of the areas of all the peptides (intact + degraded) present in the rat serum (Figure 7(a)). Each fraction was then collected and characterized by MALDI TOF/TOF (Fig. S6). A 40% degradation of DRS-DA2N was observed after 30 min, and DRS-DA2N

was totally degraded in the presence of serum for 24 h. MS/MS fragmentation of the degraded peptides, using MALDI-TOF/TOF, indicated a time-dependent N-terminal degradation (Fig. S6).

Alternatively, DRS-DA2N (300 µM) fractions previously incubated with serum for 0 (t0), 15 min (t15), 30 min (t30), or 24 h (t24 h) were recovered and incubated with cells from the mouse bone marrow for two hours at a concentration of 5 µM. Cell death was evaluated by flow cytometry. As observed in Figure 7(b), no significant differences in the percentage of dead cells could be seen in the presence of DRS-DA2N t0 or
<figure><img src="image_9.png" /><figcaption>FIGURE 7: DRS-DA2N and DRS-DA2NEQ are resistant to enzymatic degradation for 15 minutes. (a) Quantification of the remaining peptide based on relative UV absorption at 220 nm of DRS-DA2N upon incubation with rat serum for different incubation time points (n = 3 independent experiments). (b) Recovered DRS-DA2N previously submitted to serum for different time points was incubated with mouse bone marrow cells for 2 hours, and cell viability was determined. Three independent experiments were run in triplicate.</figcaption></figure>

t15. On the contrary, the percentage of dead cells started to decrease when cells were incubated with DRS-DA2N t30. When incubating cells with DRS-DA2N t24, the induction of cell death was almost completely abolished.

Both experiments indicated that DRS-DA2 degraded rapidly in the presence of proteases contained in the serum, as a consequence of which the peptide lost its immunosuppressive function.

### 3.4. DRS-DA2N Decreases Locally the Inflammation in a Mouse Model of Noninfectious Peritonitis.
As DRS-DA2 induces the death of immune cells and bacteria rapidly, in less than 30 min, without affecting the viability of erythrocytes or epithelial cells, and since it also degrades rapidly in the presence of serum, we considered the possibility of using DRS-DA2 in inflammatory pathologies that could benefit of a local treatment, which would have the advantage to decrease the risks of adverse effects.

To validate the possibility of using the peptides *in vivo* as a local anti-inflammatory treatment, we used a mouse model of noninfectious peritonitis and injected the peptides directly in the peritoneal cavity. Basically, peritonitis was induced by injecting thioglycolate 3% in the peritoneal cavity. DRS-DA2N, DRS-DA2NEQ, Scr, or the vehicle (NaCl) were intraperitoneally (i.p.) injected 14, 19, and 24 h later. A group of mice injected with NaCl only was used as a control of the induction of peritonitis. Mice were sacrificed 12 h after the last injection of the peptides or vehicle. The effect of the peptides on the number of leukocytes in the peritoneal cavity, blood, and bone marrow was analyzed by flow cytometry, with monocytes, macrophages, and neutrophils being defined on the expression of CD11b, Ly6G, and F4/80 cell surface markers.

The injection of thioglycolate 3% and the peptide vehicle (NaCl) increased the level of monocytes, macrophages, and neutrophils in the peritoneal cavity, compared to the control group (NaCl only). Three i.p. injections of DRS-DA2 after the thioglycolate 3% injection resulted in a significant decrease in the number of monocytes, macrophages, and neutrophils in the peritoneal cavity of the mice compared to

the group of mice injected with thioglycolate 3% and vehicle (NaCl) or Scr (Figure 8(a)).

To investigate whether the lesser number of leukocytes observed in the peritoneal cavity after treatment with DRS-DA2N and DRS-DA2NEQ was restricted to a local environment (peritoneal cavity) or was systemic, we evaluated the number of inflammatory cells in blood and in the bone marrow. As expected, induction of peritonitis led to an egress of monocytes and neutrophils from the bone marrow (Figure 8(b)) and an increase in blood (Figure 8(c)). Interestingly, this egress of inflammatory cells from the bone marrow and this increase in blood observed after induction of peritonitis and treatment with DRS-DA2N or Scr were conserved, whereas the egress from the bone marrow and the increase of monocytes in the blood were reduced after induction of peritonitis and treatment with DRS-DA2NEQ (Figures 8(b) and 8(c)). Thus, these results indicate that the i.p. treatment with both peptides reversed the increase of inflammatory cells in the peritoneal cavity after induction of peritonitis. However, whereas the effect of DRS-DA2N was restricted to the peritoneal cavity, DRS-DA2NEQ seemed to have a more systemic effect, as there is a significant diminution of the egress of monocytes in the bone marrow and of the increase of monocytes in blood.

### 3.5. DRS-DA2 Affects the Integrity of the Membrane of Immune Cells and Bacteria.
The rapid killing action of the peptides (under 30 min) of both leukocytes and bacteria supports evidence that the peptides induced the death of cells and bacteria in a like manner, i.e., by a nonreceptor-mediated mechanism.

As a first step, we investigated if the peptides induced the death of immune cells by directly disrupting the cytoplasmic membrane (necrosis) or by the more regulated process of apoptosis, where membrane integrity is maintained. First, to assess that DRS-DA2 induced the death of Jurkat E 6-1 cells similarly to primary leukocytes, Jurkat E 6-1 cells were incubated with DRS-DA2N or Scr at various concentrations, and viability was measured. Similarly, to what was observed on primary leukocytes, DRS-DA2N
<figure><img src="image_10.png" /><figcaption>FIGURE 8: DRS-DA2N and DRS-DA2NEQ decrease the inflammation in vivo in a mouse model of noninfectious peritonitis. (a) Number of macrophages (CD11b⁺Ly6G⁻F4/80⁺), monocytes (CD11b⁺Ly6G⁻F4/80⁻), and neutrophils (CD11b⁺Ly6G⁺) recruited to the peritoneal cavity. (b) Number of monocytes and neutrophils in the bone marrow (BM) (c) and blood. Data are given as the mean ± SEM of 3 independent experiments run with 6 mice in each group. MΦ, macrophages; Mo, monocytes; PMN, neutrophils. \*P ≤ 0.01; \*\*P ≤ 0.01.</figcaption></figure>

induced the death of Jurkat cells after 2 hours with an $LC_{50}$ of 4 µM (Figure S7). Then, to differentiate the two death pathways, Jurkat E 6-1 cells were incubated for 2 hours with DRS-DA2N or Scr at a concentration of 5 µM or with the vehicle (PBS) as a negative control, and the cells were stained with a viability dye (eFluor 780, V) and annexin V (A) (Figure 9(a)). A positive control of apoptosis was generated by exposing the cells to UV (1 mJ/cm²) for 10 min and incubating them for 4 hours at 37°C, 5% $CO_2$ prior to staining for annexin binding and viability. After incubation with DRS-DA2N, around 70% of the remaining cells were annexin and eFluor 780 positive ($A^+V^+$), indicating they died of necrosis (Figure 9(a)). As expected, around 40% of the UV-irradiated cells were in the apoptotic cells' quadrant ($A^+V^-$). Like untreated cells (negative control), hardly any cell death (<4%) was observed after the treatment with Scr, as more than 96% of cells were alive ($A^-V^-$) (Figure 9(b)). These results suggest that DRS-DA2N could induce the death of immune cells by permeabilizing the membrane leading to the loss of membrane integrity.

We next investigated if DRS-DA2N and DRS-DA2NEQ also permeabilized the membrane of the bacteria. The extent of membrane permeabilization due to the peptides' activity was evaluated by using the ONPG test on the *E. coli* ML35p strain. This mutant is constitutive for cytoplasmic β-galactosidase, lacks lac permease, and expresses a plasmid-encoded periplasmic β-lactamase. Since there is no lactose permease in this mutant, ONPG cannot cross its inner membrane to be cleaved by cytoplasmic β-galactosidase to ONP unless permeabilization of the inner membrane occurs. ONPG cleavage produces a color change that can be measured spectrophotometrically at 420 nm [24]. DRS-DA2N and DRS-DA2NEQ, as well as melittin, induced inner membrane permeabilization, whereas, even after 60 min, omiganan did not reach the plateau (Figure 10(a)),

indicating that omiganan seems to adopt another mode of action. The slight differences observed between the DRS-DA2 peptides and melittin were not significant because they probably were due to minor differences in concentrations, taking account of the very small concentrations used in this test.

The cytoplasmic membrane depolarization activity of the peptides was determined by using the membrane potential-sensitive fluorescent dye diSC₃-5 on *E. coli* membranes [25]. If bacteria permeabilization and disruption of the cytoplasmic membrane occur following contact with the peptides, an enhancement in fluorescence will be observed as a consequence of the dispersion of the fluorescent probe in the medium. Our first results on *E. coli* showed that DRS-DA2N and DRS-DA2NEQ, as well as melittin, induced rapid depolarization within 10 min (Figure 10(b)).

To go further in the study of DRS-DA2 peptide interaction with lipids, we used liposomes as a reliable model to characterize AMP action on a membrane [26]. The permeabilization of LUV membranes induced by the peptides was assessed by using the ANTS/DPX assay that can be used to measure the leakage of small molecule probes from lipid vesicles [27]. ANTS (8-aminonaphthalene-1,3,6-trisulfonic acid, disodium salt) is a highly negatively charged dye used together with the fluorescent quencher DPX (N,N'-p-xylene-bis (pyridinium bromide)) for the studies of membrane fusion or permeability. The mixture of ANTS-DPX is minimally fluorescent initially but becomes increasingly fluorescent upon dilution by leakage into the buffer. To mimic *E. coli* membranes, a mixture of POPE and POPG (75:25) LUVs was used. In this model system, DRS-DA2N and DRS-DA2NEQ were shown to act similarly as melittin, allowing a rapid increase in fluorescence when enhancing the peptide's concentration (Figure 10(c)). The $LC_{50}$ (the peptide concentration required to induce 50% leakage) of DRS-DA2N and DRS-DA2NEQ was similar,
<figure><img src="image_11.png" /><figcaption>FIGURE 9: DRS-DA2N induces the death of immune cells by membrane disruption. Jurkat E6-1 cells were incubated for two hours with DRS-DA2N, Scr, or PBS or exposed to UV for 10 min and put to rest for 4 hours, 5% CO₂ at 37°C, before being stained with annexin V and the viability dye eFluor 780. (a) Representative flow cytometry analysis of Jurkat E6-1 cells double stained with annexin V (A) and the viability dye eFluor 780 (V). (b) Percentage of cells A⁻V⁻, A⁺V⁻, A⁻V⁺, and A⁺V⁺ after the different treatments. Two experiments were run in triplicate.</figcaption></figure>

<figure><img src="image_12.png" /><figcaption>FIGURE 10: Continued.</figcaption></figure>
<figure><img src="image_13.png" /><figcaption>FIGURE 10: Bacterial membrane permeabilization. (a) *E. coli* ML35p inner membrane permeabilization by DRS-DA2 peptides at a 2 × MIC concentration in comparison with melittin or omiganan revealed by hydrolysis of ONPG. (b) Depolarization effects of DRS-DA2N, DRS-DA2NEQ, and melittin on the *E. coli* cytoplasmic membrane. (c) ANTS/DPX assay with DRS-DA2 peptides in comparison with melittin and omiganan. (d) Tryptophan blue shift (Δλmax) in the presence of liposomes produced from *E. coli* ML35p and DRS-DA2N or DRS-DA2NEQ peptides.</figcaption></figure>

whereas melittin was slightly less active (Table 4). As previously reported by Melo et al. [28], omiganan did not induce any leakage.

The tryptophan fluorescence spectrum depends on the tryptophan environment, giving information on aqueous or lipid surroundings of the indole nucleus. As the DRS-DA2 peptides contain tryptophan in position 3, the study of the tryptophan fluorescence emission spectra could give indications of the peptides' ability to insert in membranes that would be characterized by a blue shift of λmax. The tryptophan fluorescence spectra of DRS-DA2N and DRS-DA2NEQ in aqueous buffer had a maximum emission circa 355 nm. Addition of increasing concentration of LUVs made with lipids extracted directly from *E. coli* ML35p showed a large blue shift (30-35 nm) in the emission maxima of the DRS-DA2N and DRS-DA2NEQ together with an enhancement of emission intensity maxima, indicating the incorporation of the tryptophan aromatic ring into the hydrophobic medium of lipids (Figure 10(d)).

Altogether, these results indicate that similarly to what is observed for immune cells, the induction of bacterial death by DRS-DA2 involves a strong disturbance of the membrane.

## 4. Discussion

In this study, a new member of the demarseptin family, DRS-DA2, exhibiting in vitro antimicrobial and immunosuppressive activities at a micromolar range and in vivo anti-inflammatory activity; both within 30 min; was isolated from the endemic Mexican tree frog *Pachymedusa dacnicolor*. Among the recorded 3569 AMPs (APD3, https://aps.unmc.edu/) [29], there are only 32 peptides reported with both antibacterial and anti-inflammatory activities. Most of these peptides exert their anti-inflammatory activity by inhibiting the production of inflammatory cytokines and chemokines, such as TNF-alpha, IL-6, IL-1-beta, or CCL2, or increasing

the production of anti-inflammatory cytokines such as IL-10 [30], by inhibiting interaction of LPS to toll-like receptors [31] or the production of nitric oxide [32]. To our knowledge, DRS-DA2 is the first AMP to induce specifically the death of immune cells and thus regulating locally the pool of leukocytes at the site of inflammation in an in vivo inflammatory model.

Interestingly, three different forms of this peptide, DRS-DA2NEQ, DRS-DA2NE, and DRS-DA2N, appear to coexist naturally. The existence of such truncated peptides has already been reported in the skin secretions of *Phasmahyla jandaia* where bradykinin appears as a full (RPPGFSPFR) or a C-terminal truncated form (RPPGFSPF) [33], though this does not completely refute a possible degradation of the sample, leading to the loss of residues in the C-terminal part of the peptide DRS-DA2. Although this is unlikely, since all the peptides present in the other fractions are intact. The full-length peptide was predicted by Wechselberger in 1998 but had never been isolated until now [7]. DRS-DA2NEQ and DRS-DA2NE present a net charge of +4, while DRS-DA2N has a net charge of +5 and is thus slightly more charged than most of the recorded AMPs having a net charge between +2 and +4. Like numerous AMPs, and particularly those of the dermaseptin family, DRS-DA2 is structured in the alpha-helix in contact with micelles that mimic amphipathic properties of the membranes lipid bilayer, with the C-terminal region of the peptide rather unstructured, and exhibits a pronounced amphipathic character (Figures 2(a) and 2(b)). Interestingly, the short form of the peptide DRS-DA2N presents a higher percentage of helicity, indicating that it seems to be better structured. These differences in terms of the net charge and structural conformation seem to play a role in the activity of the peptide as DRS-DA2N exhibits slightly better antimicrobial and immunosuppressive activities than DRS-DA2NEQ (Tables 1 and 2). These observations are consistent with the literature as the antibacterial mechanism of action of
<table><caption>TABLE 4: Membrane perturbation studied by the ANTS/DPX assay from POPE/POPG LUVs.</caption><thead><tr><th>Peptides</th><th>LIC<sub>50</sub> (μM)</th></tr></thead><tbody><tr><td>DRS-DA2N</td><td>1.5 ± 0.3</td></tr><tr><td>DRS-DA2NEQ</td><td>2.3 ± 0.5</td></tr><tr><td>Melittin</td><td>7.2 ± 3.5</td></tr><tr><td>Omiganan</td><td>No leakage</td></tr></tbody></table>

LIC<sub>50</sub> obtained from Figure 10(c).

these kinds of peptides depends on the positive net charge and alpha-helix conformation of the peptide [34]. The detailed mechanism by which cationic AMPs inhibit bacterial growth leading to their death has not yet been totally described. However, it is now known that most of these peptides interact through their N-terminal region with the membrane before disrupting and permeabilizing it, whereby several biophysical properties of the peptide (amphipathicity, net charge, hydrophobicity, structural conformation, or flexibility) and also of the membrane (charge, conformation, curvature, flexibility, or composition) are implicated [34, 35]. In the present study, the possible mechanism of bacterial death induced by DRS-DA2 was evaluated by various biophysical techniques and showed that the peptide disrupted the bacterial membrane within 30 minutes. As the immunosuppressive effect was also observed within 30 minutes after incubating leukocytes with DRS-DA2, we hypothesized that the peptide would induce the death of the cells by necrosis, which is a mechanism of death very similar to the bacterial membrane disruption and which occurs rapidly. Indeed, using necrotic and apoptotic markers, we showed that the peptide induced necrosis rather than apoptosis.

Cancer cell membranes differ from primary cells by exhibiting more negatively charged components, greater fluidity, and cell surface area [36]. These properties play an important role in the induction of cancer cell death by enabling cationic peptides to interact better with the membrane of cancer cells than with that of primary cells. However, we could not note significant differences in the induction of death of primary versus cancer cells (Figures 3(a), S7, 4(b) and 4(c)), indicating that the biophysical properties mentioned above are not sufficient for DRS-DA2 to induce cell death. Moreover, as far as we are aware, this is the first report documenting a peptide that induces specifically the death of one type of cells that are not tumor cells, without affecting other types of eukaryotic cells at this range of concentration. The exact molecular mechanisms by which DRS-DA2 induces bacteria and leukocyte death, as well as the difference in sensitivity of DRS-DA2 on leukocytes and other eukaryotic cells, are for the moment, not fully understood. To clarify these points, further investigations will be needed.

DRS-DA2 also displays a different sensitivity on Gram-negative and Gram-positive bacteria by exhibiting an enhanced effect on Gram-negative bacteria, with a MIC and an MBC significantly lower. These findings are quite unusual, as observed by Malanovic [34]. Indeed, it has been demonstrated that the peptidoglycan composition of

the outer membrane wall of Gram-positive bacteria would function as a cell wall sponge, attracting peptides to the surface of the bacterial lipid membrane, thus potentiating the action of antimicrobial peptides by increasing their local concentration at the level of the bacterial membrane.

Nevertheless, we showed that DRS-DA2N inhibited the growth of the skin multiresistant Gram-positive strain S. aureus ATCC 700699 (MecA +), frequently responsible for nosocomial infections, and is though better than the reference antibiotic (10 times better). DRS-DA2N also inhibited the growth of the other skin Gram-positive bacteria Propionibacterium acnes, responsible for acne vulgaris, which is one of the most common skin diseases affecting more than 630 million people in the word [37]. However, even if DRS-DA2 exhibited a MIC higher than the reference antibiotic doxycycline, it still presented a good activity. It should be noted that doxycycline is used as oral treatment and can result in severe aplastic anemia [38], whereas DRS-DA2 could be used topically and locally. DRS-DA2N also inhibited the growth of two Gram-negative skin bacteria responsible for nosocomial infections, S. epidermidis ST20140436 (MecA +) and E. coli OXA-48 (carbapenemase) with MICs lower than the reference antibiotic. DRS-DA2 was also efficient against two candida species, Candida glabrata CBS138, which present an innate resistance to azole antimycotic therapy that is very effective in treating infections caused by other Candida species, and Candida albicans. Most Candida infections are benign, though they can lead to death in immunocompromised hosts. Until recently, C. glabrata was considered a relatively nonpathogenic fungal organism. However, with the increased use of immunosuppressive agents, mucosal and systemic infections caused by C. glabrata have raised significantly [39].

Most treatments used in inflammatory diseases are small drugs that interact with various pharmacological targets that exhibit poor selectivity and high toxicity that are associated with numerous side effects. Most of them present systemic effects, which in long-term therapies usually weaken the ability of the immune system to combat infections [40]. Thus, the use of peptides, and in particular, peptides exhibiting dual action, i.e., anti-inflammatory and antibacterial, could be an alternative treatment to small molecules. Compared to small molecules, peptides present high potency and selectivity, low toxicity, low risk of drug interaction, and low accumulation in tissue. Nevertheless, poor metabolic stability and rapid clearance of bioactive peptides are usually seen as a restriction in their use [40, 41]. As expected for a peptide, DRS-DA2 demonstrated poor metabolic stability as it started to degrade within one hour. However, we also showed that it induced the death of bacteria and immune cells in less than 30 min. Thus, this rapid clearance should not affect its antibacterial and immunosuppressive activities *in vivo* after a local application. Furthermore, it would have the advantage of minimizing the dissemination of the peptide in the body, thus decreasing the risks of side effects. Moreover, the fact that DRS-DA2 exhibits a rapid action is very promising as less peptide would be necessary to kill bacteria in comparison with slow-acting peptides or small molecules (time-kill greater than 2 h)
since bacteria are able to double in the number every 20 min [42]. We showed that the local application (i.p. injection) of DRS-DA2 after induction of noninfectious peritonitis reversed the number of leukocytes in the peritoneal cavity. Additional *in vivo* experiments would be necessary to confirm if the decrease observed is due to the death of leukocytes as hypothesized or to another effect on leukocytes, such as inhibition of migration. Notably, the short form DRS-DA2N exhibited a local effect, as no modulation of the number of leukocytes was observed in the bone marrow or in blood after peritonitis induction. Furthermore, as the *in vivo* effect of the peptide was validated in a short-term inflammatory model, it would be of great interest to investigate its effect on a more relevant inflammatory model, such as a chronic skin inflammatory disease, to ensure that the death induction of leukocytes does not trigger proinflammatory signals, such as the production of inflammatory cytokines, angiogenesis, or vasodilation.

## 5. Conclusions

In conclusion, to our knowledge, DRS-DA2 is the first AMP to exhibit antimicrobial activity combined with the capacity to regulate the pool of inflammatory cells by inducing specifically the death of leukocytes at a concentration within the micromolar range without being toxic to other eukaryotic cells such as erythrocytes or primary and transformed epithelial cells at that concentration. As the short form DRS-DA2N is slightly more potent at inducing the death of bacteria and leukocytes, as well as presenting a capacity to regulate the pool of inflammatory cells locally in the inflammatory model of peritonitis, it could be a promising therapeutic agent in the treatment of inflammatory diseases, and particularly, in skin inflammatory diseases.

## Abbreviations

**AMP:** Antimicrobial peptides

**BM:** Broth medium

**CD:** Circular dichroism

**DMPC:** 1,2-Dimyristoyl-sn-glycero-3-phosphatidylcholine

**DMPG:** 1,2-Dimyristoyl-sn-glycero-3-phosphatidylglycerol

**RP-HPLC:** Reversed-phase high pressure liquid chromatography

**MALDI-TOF:** Matrix-assisted laser desorption/ionization-time-of-flight

**MERS-CoV:** Middle East respiratory syndrome-related coronavirus

**MIC:** Minimal inhibitory concentration

**NK:** Natural killer

**NMR:** Nuclear magnetic resonance

**ONPG:** 2-Nitrophenyl-β-D-galactopyranoside

**PBMC:** Peripheral blood mononuclear cells

**PMN:** Polymorphonuclear

**SARS-CoV:** Severe acute respiratory syndrome coronavirus

**UV:** Ultraviolet.

## Data Availability

The data used to support the findings of this study are included within the article or within the supplementary information file.

## Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

## Acknowledgments

We thank Dr. Angel Flores Alcantar, Bryan Benainous, and M. en C. Mario Trejo Loyo for technical help, M.V.Z. Maria Elena Elizabeth Mata Moreno and M.V.Z Graciela Margarita Cabeza Pérez for animal care, and MS³U platform for access to the MS instruments. This work was supported by the grants from Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México, Grant Number: UNAM-PAPIIT AI203020 to CA and Consejo Nacional de Ciencia y Tecnología (CONACYT), Fronteras de la Ciencia 2015-02-853 to YR. We acknowledge that EAN, VMO, and EFB were the recipients of scholarships from CONACYT, Mexico. This work was also supported financially by SATT-LUTECH.

## Supplementary Materials

Supplementary 1: Figure S1: isolation and purification of a new immunosuppressor peptide, dermaseptin DRS-DA2. Supplementary 2: Table S1: NMR and refinement statistics for the structure calculation of DRS-DA2N bound to SDS micelles (12 conformers). Supplementary 3: Figure S2: far-UV CD spectra of DRS-DA2N, DRS-DA2NEQ, melittin, and Scr in Tris 10 mM. Supplementary 4: Figure S3: NMR conformational study of DRS-DA2N bound to SDS micelles. Supplementary 5: Figure S4: DRS-DA2N and DRS-DA2NEQ induce the death of mouse leukocytes. Supplementary 6: Figure S5: DRS-DA2N and DRS-DA2NEQ are not toxic for erythrocytes or epithelial cells. Supplementary 7: Figure S6: stability of the peptide DRS-DA2N in rat serum. Supplementary 8: Figure S7: DRS-DA2N induces the death of Jurkat cells. (Supplementary Materials)

## References

[1] M. Merad and J.-C. Martin, "Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages," *Nature Reviews Immunology*, vol. 20, no. 6, pp. 355-362, 2020.

[2] C. Janeway, K. Murphy, P. Travers, and M. Walport, *Inmunobiología de Janeway*, W. W. Norton and Company, New York, NY, USA, 2009.

[3] J.-L. Lau and M.-K. Dunn, "Therapeutic peptides: historical perspectives, current development trends, and future directions," *Bioorganic and Medicinal Chemistry*, vol. 26, no. 10, pp. 2700-2707, 2018.

[4] C. Auvynet and Y. Rosenberg, "Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in
innate and adaptive immunity,” *FEBS Journal*, vol. 276, no. 22, pp. 6497–6508, 2009.

[5] M. Mahlapuu, J. Håkansson, L. Ringstad, and C. Björn, “Antimicrobial peptides: an emerging category of therapeutic agents,” *Frontiers in Cellular and Infection Microbiology*, vol. 6, no. 6, p. 194, 2016.

[6] M. Drayton, J.-P. Deisinger, K.-C. Ludwig et al., “Host defense peptides: dual antimicrobial and immunomodulatory action,” *International Journal of Molecular Sciences*, vol. 22, no. 20, Article ID 11172, 2021.

[7] C. Wechselberger, “Cloning of cDNAs encoding new peptides of the dermaseptin-family,” *Biochimica et Biophysica Acta (BBA) Protein Structure and Molecular Enzymology*, vol. 1388, no. 1, pp. 279–283, 1998.

[8] C. Auvynet, P. Joanne, J. Bourdais, P. Nicolas, C. Lacombe, and Y. Rosenberg, “Dermaseptin DA4, although closely related to dermaseptin B2, presents chemotactic and Gram-negative selective bactericidal activities,” *FEBS Journal*, vol. 276, no. 22, pp. 6773–6786, 2009.

[9] M. Karas and F. Hillenkamp, “Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons,” *Analytical Chemistry*, vol. 60, no. 20, pp. 2299–2301, 1988.

[10] L. Carlier, P. Joanne, L. Khemtemourian et al., “Investigating the role of GXXXG motifs in helical folding and self-association of plasticins, Gly/Leu-rich antimicrobial peptides,” *Biophysical Chemistry*, vol. 196, pp. 40–52, 2015.

[11] S. Cardon, E. Sachon, L. Carlier et al., “Peptidoglycan potentiates the membrane disrupting effect of the carboxyamidated form of DMS-DA6, a Gram-positive selective antimicrobial peptide isolated from Pachymedusa dacnicolor skin,” *PLoS One*, vol. 13, no. 10, Article ID e0205727, 2018.

[12] P. Guntert, C. Mumenthaler, and K. Wuthrich, “Torsion angle dynamics for NMR structure calculation with the new program DYANA,” *Journal of Molecular Biology*, vol. 273, no. 1, pp. 283–298, 1997.

[13] C. Auvynet, C. B. Chanville, P. Hermand et al., “ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration,” *The FASEB Journal*, vol. 30, no. 6, pp. 2370–2381, 2016.

[14] C.-G. Starr, J. He, and W.-C. Wimley, “Host cell interactions are a significant barrier to the clinical utility of peptide antibiotics,” *ACS Chemical Biology*, vol. 11, no. 12, pp. 3391–3399, 2016.

[15] K. Kitada, E. Yamaguchi, and M. Arisawa, “Isolation of a Candida glabrata centromere and its use in construction of plasmid vectors,” *Gene*, vol. 175, no. 1-2, pp. 105–108, 1996.

[16] A.-M. Gillum, E.-Y. Tsay, and D.-R. Kirsch, “Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of *S. cerevisiae* ura3 and *E. coli* pyrF mutations,” *Molecular and General Genetics MGG*, vol. 198, no. 1, pp. 179–182, 1984.

[17] G. Gutiérrez-Escobedo, E. Orta-Zavalza, I. Castaño, and A. De Las Peñas, “Role of glutathione in the oxidative stress response in the fungal pathogen Candida glabrata,” *Current Genetics*, vol. 59, no. 3, pp. 91–106, 2013.

[18] C.-Y. Chen, G.-W. Nace, and P.-L. Irwin, “A 6×6 drop plate method for simultaneous colony counting and MPN enumeration of Campylobacter jejuni, Listeria monocytogenes, and *Escherichia coli*,” *Journal of Microbiological Methods*, vol. 55, no. 2, pp. 475–479, 2003.

[19] A. Zipperer, M.-C. Konnerth, C. Laux et al., “Human commensals producing a novel antibiotic impair pathogen colonization,” *Nature*, vol. 535, no. 7613, pp. 511–516, 2016.

[20] M. Arias and H.-J. Vogel, “Fluorescence and absorbance spectroscopy methods to study membrane perturbations by antimicrobial host defense peptides,” *Methods in Molecular Biology*, vol. 1548, pp. 141–157, 2017.

[21] M.-T. Tosteson and D.-C. Tosteson, “The sting. Melittin forms channels in lipid bilayers,” *Biophysical Journal*, vol. 36, no. 1, pp. 109–116, 1981.

[22] A.-S. Ladokhin, M.-E. Selsted, and S.-H. White, “Sizing membrane pores in lipid vesicles by leakage of co-encapsulated markers: pore formation by melittin,” *Biophysical Journal*, vol. 72, no. 4, pp. 1762–1766, 1997.

[23] F. Bongomin, S. Gago, R.-O. Oladele, and D.-W. Denning, “Global and multi-national prevalence of fungal diseases-estimate precision,” *Journal of Fungi*, vol. 3, no. 4, p. 57, 2017.

[24] R.-F. Epand, H. Sarig, A. Mor, and R.-M. Epand, “Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl,” *Biophysical Journal*, vol. 97, no. 8, pp. 2250–2257, 2009.

[25] C. El Amri, C. Lacombe, K. Zimmerman et al., “The plasticins: membrane adsorption, lipid disorders, and biological activity,” *Biochemistry*, vol. 45, no. 48, pp. 14285–14297, 2006.

[26] D. Roversi, V. Luca, S. Aureli, Y. Park, M.-L. Mangoni, and L. Stella, “How many antimicrobial peptide molecules kill a bacterium? The case of PMAP-23,” *ACS Chemical Biology*, vol. 9, no. 9, pp. 2003–2007, 2014.

[27] W.-C. Wimley, “Determining the effects of membrane-interacting peptides on membrane integrity,” *Methods in Molecular Biology*, vol. 1324, pp. 89–106, 2015.

[28] M.-N. Melo and M. A. Castanho, “Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation,” *Biochimica et Biophysica Acta (BBA) Biomembranes*, vol. 1768, no. 5, pp. 1277–1290, 2007.

[29] G. Wang, X. Li, and Z. Wang, “APD3: the antimicrobial peptide database as a tool for research and education,” *Nucleic Acids Research*, vol. 44, no. 1, pp. D1087–D1093, 2016.

[30] H. Yu, Y. Lu, X. Qiao et al., “Novel cathelicidins from pigeon highlights evolutionary convergence in avain cathelicidins and functions in modulation of innate immunity,” *Scientific Reports*, vol. 5, no. 1, Article ID 11082, 2015.

[31] E. M. Lee, A. Y. Kim, E.-J. Lee et al., “Antimicrobial effects of coprisin on wounds infected with *Staphylococcus aureus* in rats,” *Journal of Medicinal Chemistry*, vol. 56, no. 9, pp. 3546–3556, 2013.

[32] L. Wei, J. Yang, X. He et al., “Structure and function of a potent lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide,” *Journal of Medicinal Chemistry*, vol. 56, no. 9, pp. 3546–3556, 2013.

[33] B. Rates, L.-P. Silva, I.-C. Ireno et al., “Peptidomic dissection of the skin secretion of Phasmahyla jandaia (bokermann and sazima, 1978) (Anura, hylidae, phyllomedusinae),” *Toxicon*, vol. 57, no. 1, pp. 35–52, 2011.

[34] N. Malanovic and K. Lohner, “Antimicrobial peptides targeting gram-positive bacteria,” *Pharmaceuticals*, vol. 9, no. 3, p. 59, 2016.

[35] Y. Luo and Y. Song, “Mechanism of antimicrobial peptides: antimicrobial, anti-inflammatory and antibiofilm activities,” *International Journal of Molecular Sciences*, vol. 22, no. 21, Article ID 11401, 2021.

[36] D.-W. Hoskin and A. Ramamoorthy, “Studies on anticancer activities of antimicrobial peptides,” *Biochimica et Biophysica Acta (BBA) Biomembranes*, vol. 1778, no. 2, pp. 357–375, 2008.
[37] J. K. Tan and K. Bhate, "A global perspective on the epidemiology of acne," *British Journal of Dermatology*, vol. 172, no. 1, pp. 3-12, 2015.

[38] P. Singh, A. Sinha, A. Kamath, and S. Malhotra, "Very severe aplastic anemia during treatment with doxycycline," *American Journal of Therapeutics*, vol. 24, no. 4, p. e492, 2017.

[39] M. Rasheed, A. Battu, and R. Kaur, "Host-pathogen interaction in Candida glabrata infection: current knowledge and implications for antifungal therapy," *Expert Review of Anti-infective Therapy*, vol. 18, no. 11, pp. 1093-1103, 2020.

[40] S. La Manna, C. Di Natale, D. Florio, and D. Marasco, "Peptides as therapeutic agents for inflammatory-related diseases," *International Journal of Molecular Sciences*, vol. 19, no. 9, p. 2714, 2018.

[41] U. Dietrich, R. Durr, and J. Koch, "Peptides as drugs: from screening to application," *Current Pharmaceutical Biotechnology*, vol. 14, no. 5, pp. 501-512, 2013.

[42] H. G. Boman, "Antibacterial peptides: basic facts and emerging concepts," *Journal of Internal Medicine*, vol. 254, no. 3, pp. 197-215, 2003.